Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema
NCT ID: NCT05333055
Last Updated: 2025-01-24
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
TERMINATED
Total Enrollment
107 participants
Study Classification
OBSERVATIONAL
Study Start Date
2022-02-10
Study Completion Date
2024-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The DRAGONS study is a non-interventional, prospective study that will
1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) as well as other retinal pathologies, and
2. correlate a broad array of aqueous humor disease state biomarkers with DR severity, DME anti-vascular endothelial growth factor (VEGF) responsiveness, and other retinal pathologies.
1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various stages of diabetic retinopathy (DR) and diabetic macular edema (DME) as well as other retinal pathologies, and
2. correlate a broad array of aqueous humor disease state biomarkers with DR severity, DME anti-vascular endothelial growth factor (VEGF) responsiveness, and other retinal pathologies.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
NCT01168258
Diabetic Retinopathy
Diabetic Macular Edema
TERMINATED
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
NCT00457470
Diabetes Mellitus
Diabetic Retinopathy
WITHDRAWN
PHASE2
Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome
NCT05080803
Diabetic Macular Edema
COMPLETED
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
NCT02088229
Diabetic Macular Edema
COMPLETED
Quantification of Rising the Osmotic Pressure in Diabetic Intraretinal Fluid Accumulation (Diabetic Macular Oedema)
NCT00333671
Diabetic Macular Oedema
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The DRAGONS study is a non-interventional study investigating aqueous humor biomarker levels in patients with various stages of DR, DME and other retinal pathologies.
Subjects will be included in the study if at least one eye meets any of the following criteria:
Group 1 - eyes with treatment naive DR with or without DME Group 2 - eyes with DME that are incompletely responsive to anti-VEGF therapy Group 3 - eyes with various retinal conditions including eyes with DR and DME that are anti-VEGF responsive as well as non-exudative retinal pathologies such as epiretinal membrane and macular hole
The study will consist of a single visit and a retrospective chart review. The study visit will consist of:
1. Screening for eligibility;
2. Aqueous humor collection;
3. Blood collection;
4. Optical coherence tomography;
5. Optical coherence tomography angiography;
6. Fundus photography; and
7. Fluorescein angiography.
Approximately 50 microliters (or more, up to 150 microliters) of aqueous fluid will be collected according to standard clinical procedures. Plasma and serum will be collected according to standard clinical procedures, with citrated plasma being specifically collected in a plastic tube.
Subjects will be included in the study if at least one eye meets any of the following criteria:
Group 1 - eyes with treatment naive DR with or without DME Group 2 - eyes with DME that are incompletely responsive to anti-VEGF therapy Group 3 - eyes with various retinal conditions including eyes with DR and DME that are anti-VEGF responsive as well as non-exudative retinal pathologies such as epiretinal membrane and macular hole
The study will consist of a single visit and a retrospective chart review. The study visit will consist of:
1. Screening for eligibility;
2. Aqueous humor collection;
3. Blood collection;
4. Optical coherence tomography;
5. Optical coherence tomography angiography;
6. Fundus photography; and
7. Fluorescein angiography.
Approximately 50 microliters (or more, up to 150 microliters) of aqueous fluid will be collected according to standard clinical procedures. Plasma and serum will be collected according to standard clinical procedures, with citrated plasma being specifically collected in a plastic tube.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diabetic Retinopathy
Diabetic Macular Edema
Other Retinal Disorders
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Eyes with treatment naive DR with or without DME
No interventions assigned to this group
Group 2
Eyes with DME that are incompletely responsive to anti-VEGF therapy
No interventions assigned to this group
Group 3
Eyes with various retinal conditions including eyes with DR and DME that is anti-VEGF responsive as well as non-exudative retinal pathologies such as epiretinal membrane and macular hole
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1\. Subjects with at least one of the following retinal conditions in at least one eye:
* Treatment naive diabetic retinopathy (group 1 only);
* Diabetic retinopathy with DME that is incompletely responsive to anti-VEGF therapy at principal investigators discretion with retinal thickening documented on OCT (group 2 only);
* Various retinal disease including but not limited to diabetic retinopathy without DME which has previously been treated, DME which has responded to anti-VEGF therapy, neovascular age-related macular degeneration, branch or central retinal vein occlusions, epiretinal membrane, or macular hole (group 3 only)
* Treatment naive diabetic retinopathy (group 1 only);
* Diabetic retinopathy with DME that is incompletely responsive to anti-VEGF therapy at principal investigators discretion with retinal thickening documented on OCT (group 2 only);
* Various retinal disease including but not limited to diabetic retinopathy without DME which has previously been treated, DME which has responded to anti-VEGF therapy, neovascular age-related macular degeneration, branch or central retinal vein occlusions, epiretinal membrane, or macular hole (group 3 only)
Exclusion Criteria
1. Prior intraocular or subtenon steroid injection in the study eye within the prior 1 year of signing informed consent;
2. Prior focal or grid laser photocoagulation in the study eye if within 90 days of signing informed consent;
3. Prior panretinal photocoagulation in the study eye if within 90 days of signing informed consent;
4. Intraocular or refractive surgery in the study eye within 90 days of signing informed consent;
5. Systemic anti-VEGF treatment within 90 days of signing informed consent
2. Prior focal or grid laser photocoagulation in the study eye if within 90 days of signing informed consent;
3. Prior panretinal photocoagulation in the study eye if within 90 days of signing informed consent;
4. Intraocular or refractive surgery in the study eye within 90 days of signing informed consent;
5. Systemic anti-VEGF treatment within 90 days of signing informed consent
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Greater Houston Retina Research
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles C. Wykoff, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Greater Houston Retina Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retina Consultants of Texas
Bellaire, Texas, United States
Site Status
Retina Consultants of Texas
Katy, Texas, United States
Site Status
Retina Consultants of Texas
The Woodlands, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):552-63. doi: 10.1001/archopht.122.4.552.
Reference Type
BACKGROUND
Leasher JL, Bourne RR, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, Pesudovs K, Price H, White RA, Wong TY, Resnikoff S, Taylor HR; Vision Loss Expert Group of the Global Burden of Disease Study. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care. 2016 Sep;39(9):1643-9. doi: 10.2337/dc15-2171.
Reference Type
BACKGROUND
Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, Jonas JB, Keeffe J, Leasher J, Naidoo K, Pesudovs K, Resnikoff S, Taylor HR; Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013 Dec;1(6):e339-49. doi: 10.1016/S2214-109X(13)70113-X. Epub 2013 Nov 11.
Reference Type
BACKGROUND
Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994 Dec 1;331(22):1480-7. doi: 10.1056/NEJM199412013312203.
Reference Type
BACKGROUND
Mesquida M, Drawnel F, Fauser S. The role of inflammation in diabetic eye disease. Semin Immunopathol. 2019 Jul;41(4):427-445. doi: 10.1007/s00281-019-00750-7. Epub 2019 Jun 7.
Reference Type
BACKGROUND
Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S, Neves A, Passarinha LA, Tomaz CT. Evaluation of the growth factors VEGF-a and VEGF-B in the vitreous and serum of patients with macular and retinal vascular diseases. Growth Factors. 2018 Apr;36(1-2):48-57. doi: 10.1080/08977194.2018.1477140. Epub 2018 Jul 3.
Reference Type
BACKGROUND
Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res. 2016 Jan;103:253-69. doi: 10.1016/j.phrs.2015.11.027. Epub 2015 Dec 8.
Reference Type
BACKGROUND
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003 Jan;22(1):1-29. doi: 10.1016/s1350-9462(02)00043-5.
Reference Type
BACKGROUND
Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 2008 Apr;57(4):1026-33. doi: 10.2337/db07-0982. Epub 2008 Jan 3.
Reference Type
BACKGROUND
Hofman P, Blaauwgeers HG, Tolentino MJ, Adamis AP, Nunes Cardozo BJ, Vrensen GF, Schlingemann RO. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr Eye Res. 2000 Aug;21(2):637-45.
Reference Type
BACKGROUND
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):766-85.
Reference Type
BACKGROUND
Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981 Jul;88(7):583-600.
Reference Type
BACKGROUND
Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010 Jun;117(6):1064-1077.e35. doi: 10.1016/j.ophtha.2010.02.031. Epub 2010 Apr 28.
Reference Type
BACKGROUND
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11.
Reference Type
BACKGROUND
Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8.
Reference Type
BACKGROUND
Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina. 2007 Sep;27(7):816-24. doi: 10.1097/IAE.0b013e318042d32c.
Reference Type
BACKGROUND
Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505-37.
Reference Type
BACKGROUND
Writing Committee for the Diabetic Retinopathy Clinical Research Network; Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217.
Reference Type
BACKGROUND
Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 2016 Sep 7;17(9):1498. doi: 10.3390/ijms17091498.
Reference Type
BACKGROUND
Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, Gardiner TA, Lyons TJ, Hammes HP, Simo R, Lois N. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016 Mar;51:156-86. doi: 10.1016/j.preteyeres.2015.08.001. Epub 2015 Aug 18.
Reference Type
BACKGROUND
Stewart MW. Treatment of diabetic retinopathy: Recent advances and unresolved challenges. World J Diabetes. 2016 Aug 25;7(16):333-41. doi: 10.4239/wjd.v7.i16.333.
Reference Type
BACKGROUND
Maturi RK, Bleau L, Saunders J, Mubasher M, Stewart MW. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY. Retina. 2015 Aug;35(8):1604-14. doi: 10.1097/IAE.0000000000000533.
Reference Type
BACKGROUND
Wu H, Hwang DK, Song X, Tao Y. Association between Aqueous Cytokines and Diabetic Retinopathy Stage. J Ophthalmol. 2017;2017:9402198. doi: 10.1155/2017/9402198. Epub 2017 Jun 7.
Reference Type
BACKGROUND
Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013 Aug 4;19:1734-46. Print 2013.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1&ua=1.
2016 Global Report on Diabetes
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DRAGONS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema
NCT06179030
COMPLETED
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
NCT06914778
RECRUITING
Non-Responsive Diabetic Macular Edema and Spironolactone
NCT04853355
WITHDRAWN
PHASE4
A Study of Avoralstat In Participants With Diabetic Macular Edema
NCT07228559
RECRUITING
PHASE1
A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients
NCT07199777
NOT_YET_RECRUITING
PHASE2
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
NCT02302079
COMPLETED
PHASE2
Biomarkers of Diabetic Retinopathy Progression
NCT01607190
COMPLETED
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
NCT05802329
RECRUITING
PHASE1
A Single Ascending Dose Cohort Study of AG-73305 in DME Patients
NCT05301751
COMPLETED
PHASE2
Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema
NCT01702441
COMPLETED
PHASE1/PHASE2
A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)
NCT02103283
COMPLETED
PHASE1
Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy
NCT01175486
UNKNOWN
PHASE4
Multimodal Image Study of Retinal Inflammation Markers After Corticoid and Antiangiogenic Treatment in Pacients With Diabetic Macular Edema
NCT03583242
UNKNOWN
Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide
NCT02221453
COMPLETED
PHASE2
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
NCT04429503
COMPLETED
PHASE2/PHASE3
Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy
NCT02307110
COMPLETED
NA
Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography
NCT01790945
UNKNOWN
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
NCT04692688
COMPLETED
PHASE2
Comparison of Restoration in Vitreous Hemorrhage Patients With DME After or Not Removing Inner Limiting Membrane
NCT05529589
UNKNOWN
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916
ACTIVE_NOT_RECRUITING
PHASE2
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema
NCT02441907
COMPLETED
PHASE4
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
NCT04292912
TERMINATED
PHASE1
Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
NCT00320814
COMPLETED
PHASE1
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
NCT04527107
COMPLETED
PHASE2
Phase II Combination Steroid and Anti-VEGF for Persistent DME
NCT01945866
COMPLETED
PHASE2